Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
Blog
Roche wins EUA for intravenous tocilizumab in treating COVID-19
Roche announced today that it received FDA emergency use authorization (EUA) for intravenous Actemra/RoActemra in treating COVID-19. Basel, Switzerland-based Roche’s Actemra/RoActemra (tocilizumab) drug received authorization to treat COVID-19 in hospitalized adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or […]
DeviceTalks eyeing 2022 return to Boston, Minneapolis, Santa Clara
For the past 15 months, DeviceTalks has connected tens of thousands of medical professionals through a growing series of podcasts and virtual meetings. Now, we’re pleased to announce we’ll be resuming our in-person meetings in 2022. DeviceTalks will hold meetings in three of the country’s medical device hubs – Boston, Minneapolis and Silicon Valley. Each […]
Senator Manchin asks Biden to oust Woodcock over Aduhelm row
The West Virginia Senator Joe Manchin III (D-W. Va) sent a letter to President Joe Biden expressing his dismay regarding the FDA’s approval of Aduhelm (aducanumab), the controversial Alzheimer’s treatment from Biogen (NSDQ:BIIB). The nonprofit watchdog group Public Citizen sent a broadly similar letter to HHS Secretary Xavier Becerra to “express its outrage” over the approval and to demand […]
CureVac’s interim vaccine efficacy is 47% in Phase 2b/3 study
Germany-based CureVac (NSDQ:CVAC) announced that its mRNA vaccine was 47% effective against COVID-19 in a second interim analysis of a pivotal study involving approximately 40,000 participants in 10 countries. The rise of COVID-19 variants played a role in the disappointing results. At least 13 COVID-19 variants were present in the study population who contracted the […]
Frequency Therapeutics faces growing legal challenges
Hearing loss drug developer Frequency Therapeutics (NASDAQ: FREQ) is the subject of a growing number of security fraud accusations on behalf of investors. Earlier this year, things were looking up for the company’s lead product candidate, FX-322. But on March 23, Frequency Therapeutics announced that interim results suggested that FX-322 was not effective at improving […]
Martha sets 800 million patient mark for Medtronic
Can Medtronic really reach 10 times as many people as it does today? In an interview with MedtronicTalks, Geoff Martha says one year in the CEO seat has shown him the company is positioned to have a far greater impact on global health than it currently does. “We take great pride in that we impact […]
7 digital health startups you need to watch in 2021
Digital health has skyrocketed in recent years. The pandemic has only propelled its growth by keeping patients away from doctors’ offices in droves. Thanks to the continued adoption of smartphones, the growth of connected medical devices and changes in patients’ and providers’ preferences, digital health will only continue to expand through the 2020s and beyond, […]
Pfizer and BioNTech seek EMA nod for younger adolescents
After announcing that its vaccine was 100% efficacious in a Phase 3 trial involving adolescents aged 12 to 15, Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) are seeking authorization from the European Medicines Agency (EMA) to distribute the vaccine to that age group. BioNTech’s CEO, Uğur Şahin, estimated that the vaccine would be available to early adolescents in 27 European countries […]
Side effects relatively rare for Pfizer-BioNTech vaccine, study says
A recent study found that only 13.5% of recipients of the COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) had systemic side effects after the first dose. That figure climbed to 22.0% after the second dose. Conversely, just over one-third (33.7%) of recipients of the first dose of vaccine from AstraZeneca (LON:AZN) had systemic side effects, according to the […]
Hear Episode 1 of the new MedtronicTalks Podcast
A year ago, the emerging pandemic brought Medtronic’s respiratory business front-and-center as demands for ventilators shot up to save the lives of thousands of people hit with COVID-19. In this interview, the first of the MedtronicTalks Podcast Series, Medtronic’s Ariel Mactavish and Dr. John de Csepel detail how the company answered the call in many […]
